Venous Thromboembolism News and Research

RSS

γ’ fibrinogen as a disease progression marker for COVID-19

Levels of the inflammatory biomarker gamma prime fibrinogen (γ' Fbg) varies according to severity in COVID-19 patients.

28 Jan 2022

Direct effect of SARS-CoV-2 on the kidney

Researchers infected human-induced pluripotent-stem-cell (iPSC)-derived kidney organoids with SARS-CoV-2 to study the virus's direct effect on the kidney.

18 Jan 2022

Study may offer insights into novel therapeutic strategies to treat COVID-19 related blood clots

Blood clots or thromboembolic complications in patients with COVID-19 are associated with increased levels of various proteins that cause blood to clot, compared with people with blood clots unrelated to COVID-19, according to a small study by Yale Cancer Center researchers.

14 Dec 2021

SARS-CoV-2 vaccination lowers risk of several outcomes after breakthrough infection

Researchers at the University of Oxford have conducted a study showing that vaccination against coronavirus disease 2019 (COVID-19) is associated with a lower risk of several sequelae among those who experience breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Oct 2021

Decreasing length of hospitalization increases post-discharge complications for surgical patients

New study results suggest the national trend toward decreasing length of hospitalization after surgical procedures may come at the expense of an increasing proportion of complications occurring after patients leave the hospital.

25 Oct 2021

Compared to influenza, COVID-19 is more likely to cause venous thrombosis

New research published in the medRxiv* preprint server suggests that COVID-19 illness incurs a greater 90-day risk of venous thrombosis than the flu. However, arterial thrombosis remains a higher risk among people with the influenza virus.

24 Oct 2021

Large study of COVID vaccine side effects in Sweden

Recently, researchers from Sweden reported population-based, age- and sex-specific background incidence rates of conditions that represent potential COVID-19 vaccine adverse events of special interest (AESI) in the general Swedish population with the help of registered data. This study is published on the medRxiv* preprint server.

6 Oct 2021

Menopausal Hormone Therapy and Dementia

News-Medical speaks to Dr. Yana Vinogradova about her latest research into menopausal hormone therapy (MHT) and its unassociated risk to dementia.

6 Oct 2021

CXCR6/CXCL16 axis has significant role in the immuno-pathogenesis of severe COVID-19

In a study published on the preprint server medRxiv*, scientists studying the SARS-CoV-2 genome have identified a region linked with the disease severity.

16 Sep 2021

Blood clot risks are high following SARS-CoV-2 infection, not vaccination

Researchers from the University of Oxford have today announced the results of a study into thrombocytopenia (a condition with low platelet counts) and thromboembolic events (blood clots) following vaccination for Covid-19, some of the same events which have led to restricted use of the Oxford-AstraZeneca vaccine in a number of countries.

15 Sep 2021

Pregnancy complications with COVID-19

An important new article published in the Clinical Medicine Journal discusses pregnancy complicated with COVID-19.

14 Sep 2021

Researchers explore the impact of venous thromboembolism during surgery for renal cell carcinoma

Venous thromboembolism (VTE) refers to blood clots in the veins, which is a serious yet preventable medical condition and is often seen with advanced cancers.

14 Sep 2021

COVID-19 presents a higher risk of blood clots than vaccination

The current study found that people were at a slightly higher than normal risk of blood clots after receiving Oxford-AstraZeneca and Pfizer vaccines.

6 Sep 2021

CHEST releases new clinical guidelines for management of venous thromboembolism

The American College of Chest Physicians recently released new clinical guidelines for venous thromboembolism management, "Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel," that provides 29 recommendations on 17 Patients, Interventions, Comparators, Outcomes (PICO) questions, four of which have not been addressed previously.

5 Aug 2021

Risk of venous thrombosis is higher in SARS-CoV-2 infection than vaccination

A study has revealed that adenovirus vector and mRNA-COVID-19 vaccines are associated with an increased risk of thromboembolism and thrombocytopenia.

1 Aug 2021

BUSM receives $2.7 million grant to reduce disparities in cardio-oncology

With a growing need to better understand the many links between heart disease and cancer, the two leading causes of death worldwide, the American Heart Association, the world's leading voluntary organization dedicated to a world of longer, healthier lives, announced grants focused on this area of scientific research.

29 Jun 2021

COVID-19 patients with traumatic injuries have six times higher risk of complications, death

In addition to sickening and taking the lives of millions across the globe, COVID-19 complicated patient care in a range of less-direct ways, from increased incidence of heart attacks to decreased cancer screenings.

28 Jun 2021

A new guide for cancer-associated thrombosis

Ever since the association between cancer and thrombosis was reported by Jean-Baptiste Bouillaud in the early 19th century, cancer-associated thrombosis has remained a challenging domain of cancer management.

24 Jun 2021

Does SARS-CoV-2 alter the expression of molecules involved in the homeostasis of blood pressure?

A recent study finds that COVID-19 alters the expression of several molecules involved in the homeostasis of blood pressure.

22 Jun 2021

FDA approves oral pellets to treat children with venous thromboembolism

Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days.

21 Jun 2021